Free previewYou're reading the free part of this topic. The rest is included with Clinical.See what's included

Neurotrophic Keratitis

Cornea

1. Section 1

Introduction & Clinical Analogy

Exam pearl

Clinical Analogy: Imagine a sophisticated greenhouse where the glass panels (corneal epithelium) are maintained not just by water and sunlight, but by a hidden irrigation system of nerve signals (trigeminal trophic input). If you sever the irrigation pipes - the glass doesn't shatter immediately, but it slowly loses its self-repair ability, becomes fragile, cracks form (epithelial defects), and ultimately the entire structure collapses (stromal melt, perforation). Neurotrophic keratitis is exactly this: a cornea abandoned by its own nervous system, losing the trophic support needed for cellular survival, wound healing, and tear film stability.
Neurotrophic keratitis (NK) is a rare but devastating degenerative corneal disease caused by impaired trigeminal innervation. Unlike inflammatory corneal diseases, NK is fundamentally a disease of lost trophic support - the cornea is not attacked, it is simply neglected by the nervous system. This distinction drives every aspect of its management philosophy.

Neurotrophic keratitis (also called neurotrophic keratopathy) is a degenerative corneal disease resulting from impaired trigeminal sensory innervation.
This leads to corneal anesthesia or hypoesthesia, which causes breakdown of corneal epithelial integrity and impaired tear film.
Neurotrophic keratitis can ultimately progress to stromal ulceration and perforation.

Parameter	Detail
Prevalence	• fewer than 5 per 10,000 population (orphan disease)
Gender	• No significant predilection
Age	• Any age • older age is a risk factor
Laterality	• May be unilateral or bilateral • systemic sensory neuropathies can cause neurotrophic keratitis
Orphan Disease Status	• Cenegermin-bkbj (Oxervate) is a United States Food and Drug Administration (FDA)-designated orphan product for treatment of neurotrophic keratitis

Parameter	Detail
Prevalence	• fewer than 5 per 10,000 population (orphan disease)
Gender	• No significant predilection
Age	• Any age • older age is a risk factor
Laterality	• May be unilateral or bilateral • systemic sensory neuropathies can cause neurotrophic keratitis
Orphan Disease Status	• Cenegermin-bkbj (Oxervate) is a United States Food and Drug Administration (FDA)-designated orphan product for treatment of neurotrophic keratitis

Free preview ends here

15 more sections are included with the Clinical plan.

Clinical plan

Every Learn topic in full, with oral-exam questions and MCQs.